@article {TSUGU919, author = {HITOSHI TSUGU and SHINYA OSHIRO and FUMIO YANAI and FUMINARI KOMATSU and HIROSHI ABE and TAKEO FUKUSHIMA and YUKO NOMURA and SHINJI MATSUMOTO and KAZUKI NABESHIMA and KOICHI TAKANO and HIDETSUNA UTSUNOMIYA}, title = {Management of Pilomyxoid Astrocytomas: Our Experience}, volume = {29}, number = {3}, pages = {919--926}, year = {2009}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Pilomyxoid astrocytoma (PMA) shows a higher rate of recurrence and cerebrospinal fluid (CSF) dissemination than does pilocytic astrocytoma (PA). In this article, we discuss the treatment of PMA. Materials and Methods: Between 1992 and 2007, the authors treated 5 patients. Two of these were male, three female. Their ages ranged from 3 months to 11 years. Results: Three patients showed CSF dissemination on the initial radiographic examination. All patients received chemotherapy; the most commonly used combination drugs were cisplatin (CDDP)/carboplatin (CBDCA) and etoposide. When these drugs were unsuccessful, they were changed or other drugs added to the combination. After chemotherapy, four patients showed remarkable tumor regression. Nevertheless, one patient died 22 months after initial diagnosis, due to tumor progression. Conclusion: While our series was limited to a small number of patients, we have a positive impression of the value of chemotherapy. Even if initial chemotherapy is ineffective, we recommend continued CDDP/CBDCA-based chemotherapy with new drug combinations.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/29/3/919}, eprint = {https://ar.iiarjournals.org/content/29/3/919.full.pdf}, journal = {Anticancer Research} }